Six reasons why 2022 could be pivotal for US biosimilars
A new wave of litigation, pending challenges to AbbVie’s patent thicketing strategy and looming legislation mean this year could be a turning point for biologics imitators.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.